Pancreatic enzyme prescription following ivacaftor licensing: A retrospective analysis of the US and UK cystic fibrosis registries.
Rebecca CalthorpeMargaret RosenfeldChristopher H GossNicole GreenMark DerlethSiobhán B CarrAlan SmythIain StewartPublished in: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society (2024)
Licensing of ivacaftor was followed by a lower prevalence of PERT use in the eligible US population compared to pre-licensing period, as well as lower risk of PERT use in those who received treatment. Inconsistencies in US and UK CF registries were observed.